Using the molecular classification of glioblastoma to inform personalized treatment

Использование молекулярной классификации глиобластомы для информирования персонализированного лечения
Kenneth Aldape, Adriana Olar
2013-10-11

genetic and gene-expression heterogeneityglioblastomamolecular classificationtargeted drug developmenttreatment resistance and recurrence
Glioblastoma is the most common and most aggressive diffuse glioma, associated with short survival and uniformly fatal outcome, irrespective of treatment. It is characterized by morphological, genetic and gene-expression heterogeneity. The current standard of treatment is maximal surgical resection, followed by radiation, with concurrent and adjuvant chemotherapy. Due to the heterogeneity, most tumours develop resistance to treatment and shortly recur. Following recurrence, glioblastoma is quickly fatal in the majority of cases. Recent genetic molecular advances have contributed to a better understanding of glioblastoma pathophysiology and disease stratification. In this paper we review basic glioblastoma pathophysiology, with emphasis on clinically relevant genetic molecular alterations and potential targets for further drug development.
1
Clinically relevant genetic molecular alterations identified offer potential targets for future drug development and personalized treatment approaches.
2
Glioblastoma exhibits morphological, genetic, and gene-expression heterogeneity that drives treatment resistance and rapid recurrence.
3
Glioblastoma is the most common and aggressive diffuse glioma with short survival and uniformly fatal outcomes despite treatment.
4
Recent genetic and molecular advances have improved understanding of glioblastoma pathophysiology and enabled disease stratification.
5
Standard treatment—maximal surgical resection followed by radiation with concurrent and adjuvant chemotherapy—does not prevent near-universal recurrence and poor prognosis.

Glioblastoma tumors

Clinically relevant genetic/molecular alterations and their use in molecular classification to inform personalized treatment targets and drug development

Publication Details
Publication Date
2013-10-11
Journal
Publisher
ISSN
Cited by
278
Access Type
Author Information
Authors
Kenneth Aldape
Adriana Olar
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%